Rodrigo E. Alterio

Rodrigo E. Alterio

Auto-generated profile, based on publicly available information

Rodrigo E. Alterio

Department of Surgery University of Texas Southwestern Medical Center Dallas Texas USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
RARodrigo E. Alterio
Rodrigo E. Alterio
MNMadhuri B. Nagaraj
Madhuri B. Nagaraj
DSDaniel J. Scott
Daniel J. Scott
JTJuan Tellez
Juan Tellez
IRImad Radi
Imad Radi
PPPatricio M. Polanco
Patricio M. Polanco

10 September 2021 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
RARodrigo E. Alterio
Rodrigo E. Alterio
MJMichelle R. Ju
Michelle R. Ju
SWSam C. Wang
Sam C. Wang
JMJohn C. Mansour
John C. Mansour
AYAdam Yopp
Adam Yopp
MPMatthew R. Porembka
Matthew R. Porembka

11 August 2021 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JKJoshua Kronenfeld
Joshua Kronenfeld
ACAmber Collier
Amber Collier
MTMichael K. Turgeon
Michael K. Turgeon
MJMichelle Ju
Michelle Ju
RARodrigo Alterio
Rodrigo Alterio
JDJashodeep Datta
Jashodeep Datta

13 November 2022 in Global Surgical Education - Journal of the Association for Surgical Education
Verified
Journal Article
Closed access
PDF file
MNMadhuri B. Nagaraj
Madhuri B. Nagaraj
HBHayley B. Baker
Hayley B. Baker
PPPatricio M. Polanco
Patricio M. Polanco
IRImad Radi
Imad Radi
RARodrigo E. Alterio
Rodrigo E. Alterio
DSDaniel J. Scott
Daniel J. Scott

8 December 2023 in Journal of Surgical Oncology
Verified
Journal Article
Open access
JKJohn D. Karalis
John D. Karalis
MJMichelle R. Ju
Michelle R. Ju
RFRachel Feig
Rachel Feig
RERaechelle Estrella
Raechelle Estrella
MPMorgan F. Pettigrew
Morgan F. Pettigrew
SWSam C. Wang
Sam C. Wang
Background: Gastric cancer patients with malignant ascites often have poor functional status and malnutrition that preclude receipt of systemic therapies. Thus, these patients have a very poor prognosis. Beginning in 2019, our multidisciplinary gastric cancer disease‐oriented team implemented a more aggressive supportive care plan for gastric cancer patients with malignant ascites. The initiative included measures such as supplemental enteral nutrition, ascites drainage, and initiation of chemotherapy on an inpatient basis. We compared outcomes for gastric cancer patients who presented with synchronous malignant ascites treated before and after the implementation of the care plan.Methods: We performed a retrospective review of our institutional database to identify patients diagnosed with gastric adenocarcinoma and synchronous malignant ascites between 2010 and 2022. We compared overall survival (OS) between patients diagnosed from 2010 to 2018, which will be referred to as the historical control era and patients diagnosed from 2019 to 2022, which will be called the aggressive supportive care era.Results: Fifty‐four patients were included in our analysis; 31 patients were treated in the historical control time frame, and 23 patients were treated during the aggressive supportive care era. Demographic, clinical, and pathologic characteristics were similar between groups. 3% of historical controls received supplemental tube feeds at diagnosis as compared to 30% of the aggressive supportive care cohort (p < 0.01). 3% of historical controls received their first cycle of chemotherapy in the inpatient setting versus 39% of patients treated during the aggressive supportive care era (p < 0.01). The median number of chemotherapy cycles received was 5 among historical controls and 9.5 among aggressive supportive care era patients (p = 0.02). There was no difference in the number of days spent as an inpatient between the two groups. The median OS for historical control patients was 5.4 months as compared with 10.4 months for patients treated during aggressive supportive care era (p = 0.04).Conclusions: Gastric cancer patients with synchronous malignant ascites treated during a timeframe when our multidisciplinary team implemented more aggressive supportive care measures had improved OS as compared with historic controls. Our results suggest that aggressive supportive measures for these patients with highly challenging clinical issues and poor prognosis can prolong survival. Specifically, initiation of chemotherapy in the inpatient setting and supplemental nutrition should be considered for patients at high risk for treatment intolerance.

22 March 2023 in Journal of Surgical Research
Verified
Journal Article
Closed access
PDF file
RARodrigo E. Alterio
Rodrigo E. Alterio
JMJennie Meier
Jennie Meier
IRImad Radi
Imad Radi
ABArchana Bhat
Archana Bhat
JTJuan C. Tellez
Juan C. Tellez
PPPatricio M. Polanco
Patricio M. Polanco